Miniproteins & Therapeutics

This project is another demonstrative example of the power of chemical synthesis to unravel complex biological mechanisms, and of the interest of invertebrate models as a bio-inspiring source of original protein scaffolds.

It focuses on Venus Kinase Receptors (VKRs), an atypical class of receptor tyrosine kinases (RTK) discovered by J. Vicogne during his PhD on S. mansoni Tyrosine Kinases (TK). VKRs have a TK domain similar to that of the Insulin receptor and an extracellular domain containing a Venus Fly Trap (VFT) module. An arginine-induced rearrangement of the VFT conformation leads to the autophosphorylation of the TK domains and to the activation of a specific signaling pathway. VKRs are also present in many other invertebrate speciesincluding the mollusk Biomphalaria glabrata, the intermediate host of S. mansoni. In contrast, VKR are absent from its definitive human host as well as in any other vertebrate threads. VKRs play an important role in the development and reproduction of many invertebrates, including S. mansoni.

We identified a miniprotein produced by the mollusk host that interact with the VKRs of both the mollusc and the parasite S. mansoni. We could produce this protein by chemical synthesis and determine its X-ray crystal structure (see Figure below). This protein has opposite effect on host and parasite VKRs and might play a crucial role in host-parasite relationships. This miniprotein and its VKR receptors are currently the subject of intense research to decipher their binding interface through the determination of the structure of hormone-receptor complexes, and to understand their biological significance.

This WP focuses on the discovery and potentiation of cysteine-rich antimicrobial peptides (AMPs) from unique deep-sea worms as promising antibiotics against multidrug resistant (MDR) microorganisms such as Pseudomonas aeruginosa and Acinetobacter baumannii, which represent a major global public health threat. The emergence of MDR strains, mainly associated with pulmonary infections, together with ineffective and expensive therapeutics, urgently requires the development of a new generation of antimicrobials that can act through different mechanisms of action, thus offering new therapeutic options. The multi-target interaction of AMPs with the bacterial membrane makes the occurrence of AMR/MDR to AMPs more difficult compared to conventional antibiotics. Additional bioactivities, such as antibiofilm and anti-inflammatory activities, also add value to AMPs compared to conventional antibiotics. By comparing available sequences, the team was astonished to discover that unused compounds from worms living in deep-sea hydrothermal vents have natural mutations associated with physicochemical and biological properties that have taken terrestrial compounds dozens of years of laboratory optimisation before they could be used in industry.

The animals that inhabit deep-sea hydrothermal vents have an extraordinary physiology with under-explored and unique bioactive molecules that have been naturally designed and selected through millions of years of evolution to function regardless of extreme and highly variable conditions (salt, anoxia, pH 3 to 8, temperature from 4 to > 100 °C) to face high densities of Gram-negative bacteria, including bacteria of the genus Pseudomonas. Of the thousands of AMPs identified to date (mostly from soil bacteria or terrestrial animals such as insects, mammals and amphibians), only a few have reached the market due to production limitations, cytotoxic issues and reduced activity in clinically relevant environments (e.g. pH, salts, proteases). This clearly demonstrates that resistance to physiological conditions is a bottleneck in the development of AMPs and needs to be addressed in the development of a new therapeutic peptide.

The high likelihood of discovering new bioactive extremophile AMPs that are effective in vivo, is already illustrated by alvinellacin (see Figure below), a patented AMP identified by A. Tasiemski from the emblematic worm Alvinella pompejana, for which promising data have been obtained with the CBF team and with Muriel Pichavant (Openfield Team). The AMP, which can be produced by chemical synthesis, has all the hallmarks of a promising drug for the treatment of P. aeruginosa infections. It is currently the subject of extensive optimizations and structural, biophysical and biological investigations.